Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 3011

X
Drug Profile

T 3011

Alternative Names: B-015; MVR-T3011; MVR-T3011 IT; T-3 - ImmVira Pharma; T-3011

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immvira Pharma
  • Developer Immvira Pharma; Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Sarcoma
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I Ascites; Bladder cancer; Colorectal cancer
  • No development reported Skin cancer

Most Recent Events

  • 15 Mar 2024 T 3011 receives Fast Track Designation for Head and neck squamous cell cancer (Metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
  • 29 Feb 2024 China Medical University and Immvira plans a phase I trial for Colorectal cancer (Monotherapy, Combination therapy, Second-line therapy or greater, Metastatic disease) in April 2024 (Intrahepatic) (NCT06283303)
  • 01 Feb 2024 Immvira Pharma terminates a phase-II trial in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA prior to enrolment (Intratumoural), (NCT05756556),
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top